Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus

Chronic heart failure (CHF) and type 2 diabetes mellitus (DM2) and very common comorbidities with bidirectional, mutually aggravating courses. DM2 is known as an independent risk factor of cardiovascular complications whereas a higher CHF functional class is associated with increased risk of DM2. At present time, hypoglycemic drugs of the gliflozin class and the angiotensin receptor-neprilysin inhibitor (ARNI) are widely discussed in connection with their use in the treatment of patients with CHF and DM. The PARADIGM-HF study investigated effects of long-term treatment of CHF with reduced ejection fraction with presently the only representative of the ARNI class, a single supramolecular complex of valsartan-sacubitril. This medicine has already exceled enalapril at the effect not only on the incidence of nonfatal and fatal cardiovascular events but also on general mortality. Mean age of patients included into that study was 63.8±11.5 years; 21 % of them were females. In real-life clinical practice, physicians more frequently see older patients, and most of them are females, particularly with DM2. On the other hand, sodium-glucose cotransporter-2 inhibitors, including empagliflozin, significantly decreased the death rate and the frequency of CHF exacerbations in patients with DM2 and concomitant cardiovascular diseases, including CHF. This article describes a clinical case of initiating the valsartan-sacubitril treatment in combination with empagliflozin in an elderly female patient with congestive CHF with intermediate ejection fraction (EF) and comorbidities, including a history of myocardial infarction and DM2. Of interest is the rapid positive dynamics of clinical, laboratory (NT-proBNP) and instrumental (echocardiography) markers of CHF. At 3 months, the EF “recovered” from intermediate to preserved during the use of a comprehensive cardio-reno-metabolic approach. Both cardiologists and endocrinologists should definitely consider this approach in managing such patients since current cardiological drugs have additional pleiotropic metabolic effects whereas hypoglycemic drugs, in their turn, influence the cardiological prognosis.

Heart failure, diabetes mellitus, sacubitril-valsartan, empagliflozin

1. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes. Diabetes Care. 2004;27(3):699-703. https://doi.org/10.2337/diacare.27.3.699

2. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal. 2008;29(10):1224-40. https://doi.org/10.1093/eurheartj/ehn156

3. Barbarash O.L., Voyevoda M.I., Galstyan G.R., Shestakova M.V., Boytsov S.A., Aleksandrova O.Yu. et al. Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology. 2019;24(4):83- 91. https://doi.org/10.15829/1560-4071-2019-4-83-91

4. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure. 2014;16(1):103-11. https://doi.org/10.1002/ejhf.30

5. Packer M. Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care. 2018;41(1):11-3. https://doi.org/10.2337/dci17-0052

6. Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten GEHM et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154-62. https://doi.org/10.1007/s00125-012-2579-0

7. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-93. https://doi.org/10.2337/dci19-0066

8. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. The Lancet Diabetes & Endocrinology. 2017;5(5):333-40. https://doi.org/10.1016/S2213-8587(17)30087-6

9. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-164. https://doi.org/10.18087/cardio.2475

10. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609-20. https://doi.org/10.1056/NEJMoa1908655

11. Tereshchenko S.N., Romanova N.V., Zhirov I.V., Osmolovskaya Yu.F., Golitsyn S.P. Russian Registry of Patients with Chronic Heart Failure and Atrial Fibrillation (RIF-CHF): Clinical and demographic characteristics of the sample upon inclusion into the Registry. Russian Heart Failure Journal. 2016;17(6):418-26. https://doi.org/10.18087/rhfj. 2016.6.2276

12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. https://doi.org/10.1093/eurheartj/ehw128

13. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315-81. https://doi.org/10.1093/eurheartj/ehw106

14. Dedov I.I., Shestakova M.V., Mayorov A.Yu., Vikulova O.K., Galstyan G.R., Kuraeva T.L. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1-144. https://doi.org/10.14341/DM221S1

15. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155. https://doi.org/10.1001/jama.2019.13772

16. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diabetes and Vascular Disease Research. 2013;10(4):330-6. https://doi.org/10.1177/1479164112471064

17. Deaton C, Mamas MA, Rutter MK, Gibson M, Bowell S, Byrne R et al. Glucose and Insulin Abnormalities in Patients with Heart Failure. European Journal of Cardiovascular Nursing. 2011;10(2):75-87. https://doi.org/10.1016/j.ejcnurse.2010.08.007

18. Nichols GA, Moler EJ. Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes. Diabetologia. 2011;54(3):523-6. https://doi.org/10.1007/s00125-010-1965-8

19. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;20(5):853-72. https://doi.org/10.1002/ejhf.1170

20. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384-95. https://doi.org/10.1161/CIRCULATIONAHA.118.037778

21. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038

22. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380(4):347-57. https://doi.org/10.1056/NEJMoa1812389

23. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995-2008. https://doi.org/10.1056/NEJMoa1911303

24. Packer M. Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure: GLP-1 receptor signalling and neprilysin. European Journal of Heart Failure. 2018;20(6):973-7. https://doi.org/10.1002/ejhf.1185

25. Giamouzis G, Butler J. Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? The Lancet Diabetes & Endocrinology. 2017;5(5):314-5. https://doi.org/10.1016/S2213-8587(17)30089-X

26. Jordan J, Stinkens R, Jax T, Engeli S, Blaak E, May M et al. Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension: Metabolic Benefits of Sacubitril/Valsartan (LCZ696). Clinical Pharmacology & Therapeutics. 2017;101(2):254-63. https://doi.org/10.1002/cpt.455

27. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation: Heart Failure. 2016;9(1):e002560. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560

28. Damman K, Testani JM. The kidney in heart failure: an update. European Heart Journal. 2015;36(23):1437-44. https://doi.org/10.1093/eurheartj/ehv010

29. Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure. 2018;20(3):514-22. https://doi.org/10.1002/ejhf.1056

30. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015;36(30):1990-7. https://doi.org/10.1093/eurheartj/ehv186

31. Mullens W, Damman K, Harjola V-P, Mebazaa A, Brunner-La Rocca H-P, Martens P et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2019;21(2):137-55. https://doi.org/10.1002/ejhf.1369